Tioguanine

Overview

An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.

Indication

For remission induction and remission consolidation treatment of acute nonlymphocytic leukemias.

Associated Conditions

Acute Non-Lymphocytic Leukemia
Nonlymphocytic Acute myeloid leukemia

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)	2025/07/18	NCT07072585	Not Applicable	Not yet recruiting	Children's Oncology Group
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma	2024/08/01	NCT06533748	Phase 2	Recruiting	St. Jude Children's Research Hospital
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)	2024/04/30	NCT06390319	Phase 2	Recruiting	St. Jude Children's Research Hospital
DEC-C and Thioguanine for R/R AML	2024/04/08	NCT06351306	Phase 2	Withdrawn	Columbia University
Ma-Spore ALL 2020 Study	2024/03/28	NCT06336395	Phase 2	Recruiting	National University Hospital, Singapore
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia	2024/03/19	NCT06317662	Phase 2	Recruiting	National Cancer Institute (NCI)
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)	2024/01/18	NCT06210750	Phase 2	Withdrawn	National Cancer Institute (NCI)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)	2023/11/09	NCT06124157	Phase 3	Recruiting	National Cancer Institute (NCI)
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma	2019/08/02	NCT04043494	Phase 3	Recruiting	University Hospital Muenster
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy	2019/05/22	NCT03959085	Phase 3	Recruiting	Children's Oncology Group

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
TABLOID	Woodward Pharma Services LLC	69784-630	ORAL	40 mg in 1 1	4/15/2022
TABLOID	Aspen Global Inc.	76388-880	ORAL	40 mg in 1 1	8/3/2022
TABLOID	Waylis Therapeutics LLC	80725-630	ORAL	40 mg in 1 1	5/15/2023

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
LANVIS tioguanine 40mg tablet bottle	11110	Aspen Pharmacare Australia Pty Ltd	Medicine	A	8/2/1991

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
LANVIS	Aspen Pharmacare Canada Inc.	00282081	Tablet - Oral	40 MG	12/31/1974

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
TIOGUANINA ASPEN 40 MG COMPRIMIDOS	Aspen Pharma Trading Limited	52363	COMPRIMIDO	Medicamento Sujeto A Prescripción Médica	Not Commercialized
LANVIS 40 MG COMPRIMIDOS	Aspen Pharma Trading Limited	84019	COMPRIMIDO	Medicamento Sujeto A Prescripción Médica	Commercialized

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

Molecular Testing and Targeted Therapies Transform Treatment Landscape for Pediatric Low-Grade Gliomas

12 days ago

Comprehensive molecular testing using NGS panels and methylation profiling has become foundational for accurately diagnosing pediatric low-grade gliomas and identifying actionable mutations like BRAF alterations.

Integrated Pharmacists Significantly Improve IBD Treatment Outcomes and Cost Savings

8 months ago

A recent study demonstrates that IBD patients under direct pharmacist care showed 87.9% adherence to thiopurine medications compared to 65.7% under general practitioner guidance.

Pharmacogenetic Testing Could Benefit Most Cancer Patients, UK Study Finds

10 months ago

A UK study analyzing whole genome sequencing data reveals that 62.7% of cancer patients possess genetic changes increasing their risk of adverse reactions to common oncology drugs.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access